WASHINGTON (AP) — An analysis by U.S. regulators says Johnson & Johnson’s single-dose vaccine provides strong protection against severe COVID-19. The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot. The FDA is expected to make a final decision within days. If the FDA clears the J&J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.